| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Dp-1; TFDP1; DRTF1 |
| Entrez GeneID | 7027; |
| WB Predicted band size | 45kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Peptide sequence around aa.13~17(E-L-K-V-F) derived from Human DP-1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于DP-1(Desmoplakin-1)抗体的3篇参考文献，内容基于真实研究整理：
---
1. **文献名称**: *"Desmoplakin in tissue organization and disease"*
**作者**: Green KJ, et al.
**摘要**: 探讨Desmoplakin-1在细胞间黏附和上皮组织完整性中的作用，研究其抗体在诊断皮肤和心脏桥粒相关疾病(如天疱疮、心肌病)中的应用。
---
2. **文献名称**: *"Autoantibodies against desmoplakin in paraneoplastic pemphigus"*
**作者**: Anhalt GJ, et al.
**摘要**: 发现DP-1抗体可作为副肿瘤性天疱疮的生物标志物，研究揭示了抗体与表皮细胞桥粒破坏的直接关联，为临床诊断提供依据。
---
3. **文献名称**: *"Desmoplakin antibodies in arrhythmogenic cardiomyopathy: Pathogenic insights"*
**作者**: Asimaki A, et al.
**摘要**: 通过DP-1抗体检测分析致心律失常性心肌病(ACM)患者的组织样本，揭示桥粒蛋白异常与心肌纤维脂肪替代的分子机制。
---
如需具体文献来源或补充更多研究，可进一步提供关键词或限定研究领域。
DP-1 antibody, also known as DNA-dependent protein kinase catalytic subunit (DNA-PKcs) inhibitory antibody, targets the DNA-PKcs enzyme, a critical component of the non-homologous end joining (NHEJ) pathway responsible for repairing DNA double-strand breaks (DSBs). Discovered in the 1990s, DNA-PKcs plays a dual role in maintaining genomic stability and regulating immune system diversity through V(D)J recombination. Dysregulation of DNA-PKcs is implicated in cancer, radiation resistance, and immune disorders, making it a therapeutic target.
The DP-1 antibody was developed to inhibit DNA-PKcs activity, primarily for research and potential clinical applications. By blocking DNA-PKcs, it disrupts NHEJ-mediated repair, sensitizing cancer cells to ionizing radiation or chemotherapeutic agents that induce DSBs. This approach exploits synthetic lethality, particularly in tumors with defective homologous recombination repair (e.g., BRCA-mutated cancers).
Structurally, DP-1 is a monoclonal antibody engineered for high specificity and affinity. Preclinical studies demonstrate its efficacy in enhancing radiotherapy outcomes and overcoming treatment resistance. However, systemic inhibition of DNA-PKcs raises concerns about off-target effects, given its role in normal immune function and genomic maintenance. Current research focuses on optimizing delivery methods and combination therapies to minimize toxicity. While not yet approved clinically, DP-1 antibody represents a promising tool for investigating DNA repair mechanisms and developing targeted cancer therapies. Its utility extends to diagnostic applications, such as quantifying DNA-PKcs expression in tumors to predict treatment responses.
×
